| http://dbpedia.org/ontology/abstract
|
تيروتروبان هو عامل مضاد للصفيحات وضعت من ق … تيروتروبان هو عامل مضاد للصفيحات وضعت من قبل مختبرات سيرفير. وقد تم اختباره للوقاية الثانوية من المضاعفات الحادة في المرحلة الثالثة من التجارب السريرية PERFORM (الوقاية من الأمراض القلبية الوعائية والقلبية والأوعية الدموية مع تيروتروبان في المرضى الذين يعانون من التقرح الدماغي أو الجلطة الدماغية أو الشق الجراحي) تم إيقاف الدراسة قبل الأوان، وبالتالي لا يمكن تحديد ما إذا كان تيروتروبان له تأثير أفضل من الأسبرين. كان تيروتروبان له تأثير أفضل من الأسبرين.
, Terutroban é um agente antiplaquetário des … Terutroban é um agente antiplaquetário desenvolvido pelos laboratórios Servier. Desde 2008 é testado para a prevenção secundária de complicações trombóticas agudas no ensaio clínico de Fase III PERFORM. Terutroban é um antagonista seletivo dos receptores de tromboxano.sta seletivo dos receptores de tromboxano.
, Terutroban is an antiplatelet agent develo … Terutroban is an antiplatelet agent developed by Servier Laboratories. It is a selective thromboxane prostanoid (TP) antagonist and is an orally active drug in clinical development for the secondary prevention of acute thrombotic complications. It has been tested in the Phase III clinical trial PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack). The study was prematurely stopped and it could not be determined whether terutroban has a better effect than aspirin. The 2011 clinical trial that studied the antiplatelet agent versus aspirin found that it was not superior in the prevention of cerebral and cardiovascular ischaemic events, although it was significantly better in patients who already suffered previous stroke to the qualifying event. Researchers from the University of Milan also found in a new research that terutroban can prevent the development of aorta hyperplasia and has beneficial effects on fibrotic processes, leading to the conclusion that it has beneficial effects in preventing or retarding atherogenesis. in preventing or retarding atherogenesis.
|
| http://dbpedia.org/ontology/casNumber
|
165538-40-9
, (sodiumsalt)
|
| http://dbpedia.org/ontology/fdaUniiCode
|
A6WX9391D8
|
| http://dbpedia.org/ontology/pubchem
|
9938840
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Terutroban_acid_skeletal.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageID
|
19147078
|
| http://dbpedia.org/ontology/wikiPageLength
|
5277
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1071048140
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Vasoconstriction +
, http://dbpedia.org/resource/Sodium +
, http://dbpedia.org/resource/Thromboxane_receptor +
, http://dbpedia.org/resource/Servier_Laboratories +
, http://dbpedia.org/resource/Category:Sulfonamides +
, http://dbpedia.org/resource/Category:Propionic_acids +
, http://dbpedia.org/resource/Phase_III_clinical_trial +
, http://dbpedia.org/resource/Platelet_aggregation +
, http://dbpedia.org/resource/Category:Chlorobenzenes +
, http://dbpedia.org/resource/Category:Aminotetralins +
, http://dbpedia.org/resource/Aspirin +
, http://dbpedia.org/resource/Category:Antiplatelet_drugs +
, http://dbpedia.org/resource/Antiplatelet_agent +
|
| http://dbpedia.org/property/atcPrefix
|
none
|
| http://dbpedia.org/property/c
|
20
|
| http://dbpedia.org/property/casNumber
|
165538
|
| http://dbpedia.org/property/chemspiderid
|
8114465
|
| http://dbpedia.org/property/cl
|
1
|
| http://dbpedia.org/property/eliminationHalfLife
|
-36000.0
|
| http://dbpedia.org/property/h
|
22
|
| http://dbpedia.org/property/iupacName
|
3
|
| http://dbpedia.org/property/legalStatus
|
Investigational
|
| http://dbpedia.org/property/n
|
1
|
| http://dbpedia.org/property/o
|
4
|
| http://dbpedia.org/property/pubchem
|
9938840
|
| http://dbpedia.org/property/routesOfAdministration
|
Oral
|
| http://dbpedia.org/property/s
|
1
|
| http://dbpedia.org/property/smiles
|
CC1=CCCCO
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
HWEOXFSBSQIWSY-MRXNPFEDSA-N
|
| http://dbpedia.org/property/unii
|
A6WX9391D8
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
407704475
|
| http://dbpedia.org/property/watchedfields
|
changed
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:CAS +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Blood-drug-stub +
, http://dbpedia.org/resource/Template:Antithrombotics +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Stdinchicite +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Prostanoidergics +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Chlorobenzenes +
, http://dbpedia.org/resource/Category:Sulfonamides +
, http://dbpedia.org/resource/Category:Propionic_acids +
, http://dbpedia.org/resource/Category:Antiplatelet_drugs +
, http://dbpedia.org/resource/Category:Aminotetralins +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Agent +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Terutroban?oldid=1071048140&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Terutroban_acid_skeletal.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Terutroban +
|
| owl:sameAs |
http://pt.dbpedia.org/resource/Terutroban +
, http://yago-knowledge.org/resource/Terutroban +
, https://global.dbpedia.org/id/4vaTe +
, http://dbpedia.org/resource/Terutroban +
, http://ar.dbpedia.org/resource/%D8%AA%D9%8A%D8%B1%D9%88%D8%AA%D8%B1%D9%88%D8%A8%D8%A7%D9%86 +
, http://www.wikidata.org/entity/Q7705345 +
, http://rdf.freebase.com/ns/m.04ld62g +
, http://sr.dbpedia.org/resource/Terutroban +
, http://sh.dbpedia.org/resource/Terutroban +
|
| rdf:type |
http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/Antibacterial102716205 +
, http://dbpedia.org/class/yago/Medicine103740161 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/CausalAgent100007347 +
, http://dbpedia.org/class/yago/WikicatAntiplateletDrugs +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/WikicatSulfonamides +
, http://dbpedia.org/class/yago/SulfaDrug104352070 +
, http://dbpedia.org/class/yago/Agent114778436 +
, http://dbpedia.org/class/yago/Substance100020090 +
, http://dbpedia.org/class/yago/Drug103247620 +
|
| rdfs:comment |
تيروتروبان هو عامل مضاد للصفيحات وضعت من ق … تيروتروبان هو عامل مضاد للصفيحات وضعت من قبل مختبرات سيرفير. وقد تم اختباره للوقاية الثانوية من المضاعفات الحادة في المرحلة الثالثة من التجارب السريرية PERFORM (الوقاية من الأمراض القلبية الوعائية والقلبية والأوعية الدموية مع تيروتروبان في المرضى الذين يعانون من التقرح الدماغي أو الجلطة الدماغية أو الشق الجراحي) تم إيقاف الدراسة قبل الأوان، وبالتالي لا يمكن تحديد ما إذا كان تيروتروبان له تأثير أفضل من الأسبرين. كان تيروتروبان له تأثير أفضل من الأسبرين.
, Terutroban is an antiplatelet agent develo … Terutroban is an antiplatelet agent developed by Servier Laboratories. It is a selective thromboxane prostanoid (TP) antagonist and is an orally active drug in clinical development for the secondary prevention of acute thrombotic complications. Researchers from the University of Milan also found in a new research that terutroban can prevent the development of aorta hyperplasia and has beneficial effects on fibrotic processes, leading to the conclusion that it has beneficial effects in preventing or retarding atherogenesis. in preventing or retarding atherogenesis.
, Terutroban é um agente antiplaquetário des … Terutroban é um agente antiplaquetário desenvolvido pelos laboratórios Servier. Desde 2008 é testado para a prevenção secundária de complicações trombóticas agudas no ensaio clínico de Fase III PERFORM. Terutroban é um antagonista seletivo dos receptores de tromboxano.sta seletivo dos receptores de tromboxano.
|
| rdfs:label |
Terutroban
, تيروتروبان
|
